<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294099</url>
  </required_header>
  <id_info>
    <org_study_id>05-0141</org_study_id>
    <nct_id>NCT00294099</nct_id>
  </id_info>
  <brief_title>H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults</brief_title>
  <official_title>A Phase I-II, Randomized, Controlled, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Elderly Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare how the body reacts to different strengths of the new
      A/H5N1 flu vaccine when given with the addition of aluminum hydroxide adjuvant and provide
      dosing information. How the body's immune system responds to the new H5N1vaccine with
      aluminum hydroxide approximately 1 month following receipt of 2 doses of vaccine will also be
      evaluated. The vaccine is given as an injection or shot in the arm. Volunteer participants in
      this study will be 600 healthy elderly adults, aged 65 years and older. Participants will be
      randomly assigned to 4 different dosage groups of vaccine, either with or without adjuvant,
      for a total of 8 different groups. Volunteers will participate in the study for 7 months.
      Each individual will receive two vaccinations, the second 28 days after the first. In
      addition to visits for these vaccinations, subjects will return to the clinic for physical
      evaluations and blood sample collection 6 times during the course of this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, controlled, dose-ranging, Phase I-II study in healthy
      ambulatory elderly adults. The primary objectives are to: determine the dose-related safety
      of subvirion-inactivated H5N1 vaccine adjuvanted with aluminum hydroxide in healthy elderly
      adults (65 years of age and older); determine the potential for aluminum hydroxide to enhance
      the immune response to subvirion inactivated H5N1 vaccine in healthy elderly adults
      approximately 1 month following receipt of 2 doses of vaccine; and provide information for
      the selection of the best dosage level for further studies. A secondary objective is to
      evaluate dose-related immunogenicity and the percent of subjects responding approximately 1
      and 7 months after the first vaccination. Approximately 600 elderly subjects are planned for
      enrollment. Subjects will be screened for health status by history and targeted physical
      examination. Subjects who meet the entry criteria for the study will be randomized into 8
      groups to receive 2 doses of nonadjuvanted or aluminum hydroxide-adjuvanted influenza A/H5N1
      vaccine containing 3.75, 7.5, 15, or 45 micrograms of hemagglutinin (HA) by intramuscular
      injection. The first vaccination will occur on Day 0. Symptoms and signs will be assessed in
      the clinic for at least 15 minutes after inoculation, and subjects will maintain a memory aid
      to record oral temperature and systemic and local adverse events (AEs) for 7 days after each
      immunization. Subjects will be encouraged to take their temperature around the same time each
      day. All subjects will return to the clinic on Days 2 and 8 after each vaccination for
      assessment of AEs and concomitant medications, as well as a targeted physical examination if
      indicated. Memory aids will be reviewed at each visit. At approximately Day 28 after the
      first vaccination, subjects will return to the clinic for blood sample collection and safety
      follow-up, followed by a second vaccination. Safety follow-up will be identical to that
      performed after the first vaccination. Approximately 56 days after first immunization (or
      about 28 days after the second vaccination), subjects will return to the clinic for
      immunogenicity blood sample collection, AE and concomitant medication assessments, and
      targeted physical examinations (if indicated). At approximately Day 208 (7 months after the
      first vaccination), subjects will return to the clinic for a final immunogenicity blood
      sample collection and for follow-up, which includes a targeted physical examination if
      indicated. The duration of the study treatment for each subject will be about 7 months. The
      primary study endpoints include: AE or serious adverse event (SAE) information; proportion of
      subjects in each dose group achieving a serum neutralizing antibody titer of greater than or
      equal to 1:40 against influenza A/H5N1 virus 28 days after receipt of the second dose of
      vaccine; proportion of subjects in each dose group achieving a serum hemagglutination
      inhibition (HAI) antibody titer of greater than or equal to 1:40 against the influenza A/H5N1
      virus 28 days after receipt of the second dose of vaccine; geometric mean titer (GMT) and
      frequency of 4-fold or greater increases in neutralizing antibody titers in each group 28
      days after receipt of the second dose of vaccine; and GMT and frequency of 4-fold or greater
      increases in serum HAI antibody titers in each group 28 days after receipt of the second dose
      of vaccine. The secondary endpoints include: GMT and frequency of 4-fold or greater increases
      in neutralizing antibody titers in each group 1 month and 7 months after receipt of the first
      dose of vaccine; GMT and frequency of 4-fold or greater increases i
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GMT and frequency of 4-fold or greater increases in serum HAI antibody titers in each group 28 days after receipt of the second dose of vaccine.</measure>
    <time_frame>Approximately day 56.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers in each group 28 days after receipt of the second dose of vaccine.</measure>
    <time_frame>Approximately day 56.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects in each dose group achieving a serum hemagglutination inhibition (HAI) antibody titer of greater than or equal to 1:40 against the influenza A/H5N1 virus 28 days after receipt of the second dose of vaccine.</measure>
    <time_frame>Approximately day 56.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects in each dose group achieving a serum neutralizing antibody titer of greater than or equal to 1:40 against the influenza A/H5N1 virus 28 days after receipt of the second dose of vaccine.</measure>
    <time_frame>Approximately day 56.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event (AE) or serious adverse event (SAE) information (solicited in the clinic and via memory aids, concomitant medications, and periodic targeted physical assessment).</measure>
    <time_frame>Adverse events will be collected through 28 days following the 2nd dose of vaccine (day 56). Serious adverse events will be collected throughout the study through day 208.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of serum antibody responses against antigenically drifted variants of H5N1 influenza virus.</measure>
    <time_frame>Day 0, and at days 28, 56, and 208 after the first immunization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT and frequency of 4-fold or greater increases in serum HAI antibody titers in each group 1 month and 7 months after receipt of the first dose of vaccine.</measure>
    <time_frame>Day 0, and at days 28, 56, and 208 after the first immunization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT and frequency of 4-fold or greater increases in neutralizing antibody titers in each group 1 month and 7 months after receipt of the first dose of vaccine.</measure>
    <time_frame>Day 0, and at days 28, 56, and 208 after the first immunization.</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aluminum hydroxide</intervention_name>
    <description>Aluminum hydroxide adjuvant.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)</intervention_name>
    <description>Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are ambulatory adults aged 65 and older

          -  Are in good health, as determined by vital signs (heart rate less than 100 bpm, blood
             pressure [systolic less than or equal to 160 mm Hg and diastolic less than or equal to
             90 mm Hg] oral temperature less than 100.0Â°F), medical history to ensure stable
             medical condition, and targeted physical examination based on medical history

          -  Are able to understand and comply with planned study procedures

          -  Provide written informed consent prior to initiation of any study procedures

        Stable medical condition - no change in prescription medication, dose, or frequency of
        medication in the last 3 months and health outcomes of the specific disease are considered
        to be within acceptable limits in the last 6 months. Any change that is due to change of
        health care provider, insurance company, etc, or that is done for financial reasons, as
        long as in the same class of medication will not be considered a violation of this
        inclusion criterion. Any change in prescription medication due to improvement of a disease
        outcome will not be considered a violation of this inclusion criterion.

        Exclusion Criteria:

          -  Have a known allergy to eggs or other components of the vaccine (including gelatin,
             formaldehyde, octoxinol, thimerosal, aluminum hydroxide, and chicken protein).

          -  Have immunosuppression as a result of an underlying illness or treatment, or used
             anticancer chemotherapy or radiation therapy within the preceding 36 months.

          -  Have any malignancy (excluding nonmelanotic skin cancer) or lymphoproliferative
             disorder diagnosed or treated actively during the past 5 years.

          -  Have long-term use of oral steroids, parenteral steroids, or high-dose inhaled
             steroids ( &gt; 800 micrograms/day of beclomethasone dipropionate or equivalent) within
             the preceding 6 months (Nasal and topical steroids are allowed.)

          -  Have a diagnosis of schizophrenia, Bi-polar disease or other major psychiatric
             diagnosis.

          -  Have been hospitalized for psychiatric illness, history of suicide attempt or
             confinement for danger to self or others.

          -  Are receiving psychiatric drugs (aripiprazole, clozapine, ziprasidone, haloperidol,
             molindone, loxapine, thioridazine, thiothixene, pimozide, fluphenazine, risperidone,
             mesoridazine, quetiapine, trifluoperazine, chlorprothixene, chlorpromazine,
             perphenazine, trifluopromazine, olanzapine, carbamazepine, divalproex sodium, lithium
             carbonate or lithium citrate.) Subjects who are receiving a single antidepressant drug
             and stable for at least 3 months prior to enrollment, without de-compensating symptoms
             will be allowed to be enrolled in the study.

          -  Have a history of receiving immunoglobulin or other blood product within the 3 months
             prior to enrollment in this study.

          -  Have received any other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrollment in this study.

          -  Have an acute or chronic medical condition that, in the opinion of the investigator,
             would render vaccination unsafe or would interfere with the evaluation of responses.
             These conditions include, but are not limited to: history of significant renal
             impairment (dialysis and treatment for kidney disease, including diabetic and
             hypertensive kidney disease); subjects with diabetes mellitus, well-controlled with
             oral agents may enroll as long there has been no dose adjustment within the past 6
             months; insulin-dependent diabetes is excluded; cardiac insufficiency, if heart
             failure is present (New York Heart Association Functional Class III or IV); an
             arteriosclerotic event during the 6 months prior to enrollment (e.g., history of
             myocardial infarction, stroke, recanalization of femoral arteries, or transient
             ischemic attack).

          -  Have a history of severe reactions following immunization with influenza virus
             vaccines.

          -  Have an acute illness, including an oral temperature greater than 100.4 degrees F,
             within 1 week prior to vaccination.

          -  Received an experimental agent (vaccine, drug, biologic, device, blood product or
             medication) within 1 month prior to enrollment in this study, or expects to receive an
             experimental agent during the 7- to 8-month study period.

          -  Have any condition that would, in the opinion of the site investigator, place the
             subject at an unacceptable risk of injury or render the subject unable to meet the
             requirements of the protocol.

          -  Participated in an influenza A/H5 vaccine study in the past in a group receiving
             vaccine (but does not exclude documented placebo recipients).

          -  Have a known active human immunodeficiency virus, hepatitis B, or hepatitis C
             infection.

          -  Have a history of alcohol or drug abuse in the last 5 years.

          -  Planned to travel outside of the USA in the time between the first vaccination and 56
             days following the first vaccination.

          -  Have any diagnosis of dementia or associated concomitant medications (e.g., Aricept)
             used for treating dementia.

          -  Have a history of Guillain Barre syndrome.

          -  Have any condition that the investigator believes may interfere with successful
             completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH, Winokur P, Belshe R, Graham IL, Noah DL, Guo K, Hill H. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13;27(37):5091-5. doi: 10.1016/j.vaccine.2009.06.057. Epub 2009 Jul 3.</citation>
    <PMID>19577636</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2006</study_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>A/H5N1, Influenza, Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

